Claim your FREE Gift & Newsletter. Just enter your... E-MAIL ADDRESS

First Name


Don't worry -- your e-mail address is totally secure.
I promise to use it only to send you Prospering With Arthritis.

Get Back Into the Swing of Things!

Get the Best Bang for Your Buck... Click Here

If  this website was helpful, 
Click below to... 

Joint Pain Forum – News you can use!

back to ARCHIVED Arthritis News articles

Pfizer says 17 European countries extend Celebrex arthritis drug label


AFX News Limited

LONDON (AFX) - Pfizer Inc said 17 European countries have agreed to extend the Celebrex drug label to include symptomatic relief in the treatment of ankylosing spondylitis in adults, a form of arthritis that affects the spine. Each of the 17 countries will now individually update the licence for Celebrex to include the new labelling, following applicable local procedures.

The company said once each country updates its labelling, Celebrex will be the first oral selective COX-2 inhibitor available in Europe to treat the condition. Ankylosing spondylitis affects up to 0.9 pct of Europeans, Pfizer (nyse: PFE - news - people ) said in a research update.

back to ARCHIVED Arthritis News articles

Bookmark This Page...
AddThis Social Bookmark Button

Privacy | Terms

About Us